Skip to main
INCY
INCY logo

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 35 analyst ratings
Buy
Strong Buy 34%
Buy 20%
Hold 40%
Sell 6%
Strong Sell 0%

Bulls say

Incyte's fourth quarter results were encouraging, with Jakafi generating $773 million, surpassing expectations due to strong demand trends and limited competition impact. The firm's recent approval of Opzelura has shown promising efficacy in treating atopic dermatitis and chronic prurigo, which contributes to a positive outlook for Incyte's growth trajectory. Analysts view Incyte's existing commercial legacy business as a solid revenue foundation, complemented by a promising pipeline that may offset challenges such as the upcoming Jakafi patent cliff in 2028, suggesting sustained growth potential of approximately 5%-7%.

Bears say

Incyte faces significant financial challenges primarily due to eroding pricing power for its leading drug Jakafi and the potential for poor performance from its earlier-stage pipeline, raising concerns about the viability of future revenue streams. The company is also at risk of slowed adoption of its marketed drugs, difficulties in extending Jakafi's life cycle, and increased competition that could further impact sales growth. Additionally, the lack of compelling clinical data for its drugs, alongside potential safety concerns and pricing pressures, could adversely affect investor confidence and negatively influence the stock's performance.

Incyte (INCY) has been analyzed by 35 analysts, with a consensus rating of Buy. 34% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 35 analysts, Incyte (INCY) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $82.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $82.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.